ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health Services Research"

  • Abstract Number: 2610 • ACR Convergence 2024

    Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial

    Johannes Knitza1, Johanna Mucke2, Manuel Grahammer3, Sebastian Kuhn1, Nicolas Vuillerme4, Felix Muehlensiepen5, Gerhard Krönke6, Georg Schett7, Ann-Christin Pecher8 and Martin Krusche9, and the TELERA Study Group, 1Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, 2Heinrich-Heine-University, Duesseldorf, Germany, 3ABATON, Berlin, Germany, 4AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, 5Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, 6Rheumatology, Charité, Berlin, Germany, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, 9III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany

    Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
  • Abstract Number: 0137 • ACR Convergence 2024

    The Problem of Pain in Rheumatology: Sociodemographic and Disease-related Correlates of Agreement Between Structured Data Elements and Clinical Notes in Chronic Pain Documentation Practices in EHR

    Tahmina Begum1, Bhagyavalli Veeranki1, Ogenna Chike1 and Titilola Falasinnu2, 1Stanford School of Medicine, Stanford, 2Stanford School of Medicine, Palo Alto, CA

    Background/Purpose: To create greater precision in case definitions for chronic pain in EHRs, we recently identified 15 different case definitions for chronic pain using structured…
  • Abstract Number: 0437 • ACR Convergence 2024

    Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Deirdre Quinn1, Florentina Sileanu1, Gregory Procario1, Shannon Mitchell1 and Mehret Birru Talabi2, 1VA Pittsburgh Healthcare System, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Veterans who utilize Department of Veterans Affairs (VA) maternity benefits, nearly half (42%) of whom represent racial or ethnic minority groups, have a high…
  • Abstract Number: 1053 • ACR Convergence 2024

    Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases

    Kai Sun1, Lisa Carnago2, Isaac Smith3, Brian Andonian1, Stephen Balevic1, Ankoor Shah1, Catherine Sims4, Kathryn Pollak5, Amy Corneli5, Hayde Bosworth5 and Megan Clowse6, 1Duke University, Durham, NC, 2Duke Health, Hillsborough, NC, 3Duke University Hospital, Durham, NC, 4Duke University, Knightdale, NC, 5Duke University, Durham, 6Duke University, Chapel Hill, NC

    Background/Purpose: Medication nonadherence is as high as 75% among patients with rheumatic diseases, leading to increased morbidity, mortality, and cost. Existing adherence interventions tend to…
  • Abstract Number: 1743 • ACR Convergence 2024

    What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?

    Jing Zhao1, Urbano Sbarigia2, Jackie Kwong1, Chinmayi Naik3, Federico Zazzetti4, Nancy Shadick3 and Michael Weinblatt5, 1Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, 2Johnson & Johnson Innovative Medicine, Brussels, Belgium, 3Brigham and Women’s Hospital, Boston, MA, 4Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 5Brigham and Women's Hospital/ Harvard Medical School, Waban, MA

    Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
  • Abstract Number: 2619 • ACR Convergence 2024

    Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients

    Tali Eviatar1, Iftach Sagy2, Elad Brav2, Amir Bieber3, Victoria Furer4 and Ori Elkayam5, 1Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, 2Soroka Medical Cenrter, beer sheva, Israel, 3Emek Medical Center, Clalit Health Services, Raanana, Israel, 4Tel Aviv Medical Center, Tel Aviv, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
  • Abstract Number: 0165 • ACR Convergence 2023

    Hypothyroidism Is Associated with Worse Clinical and Utilization Outcomes After Primary Total Knee Arthroplasty

    Sumanth Chandrupatla1, Kranti Rumalla2 and Jasvinder Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2Northwestern School of Medicine, Chicago, IL

    Background/Purpose: Limited information is available regarding how medical comorbidities affect the outcomes of total knee arthroplasty (TKA). The association of medical comorbidities with post-TKA outcomes…
  • Abstract Number: 0805 • ACR Convergence 2023

    De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis

    Jiha Lee1, Navasuja Kumar1, Mohammed Kabeto1, Andrzej Galecki1, Chiang-Hua Chang1, Namrata Singh2, Raymond Yung3, Una Makris4 and Julie Bynum1, 1University of Michigan, Ann Arbor, MI, 2University of Washington, Bellevue, WA, 3Michigan Medicine, Ann Arbor, MI, 4UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Biologic disease modifying anti-rheumatic drugs (bDMARDs) such as anti-tumor necrosis factors(anti-TNFs) improve clinical and radiographic outcomes in rheumatoid arthritis (RA). However, their use is…
  • Abstract Number: 1351 • ACR Convergence 2023

    HPV Vaccination in Adolescent and Young Adult Patients Seen in an Academic Rheumatology Center

    Caroline Siegel1, Lauren Robinson1, Deanna Jannat-Khah1, Avi Mikhaylov1, Nancy Pan1 and Lisa Sammaritano2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Adolescent and young adults (AYAs) with rheumatic disease (RD) may face disproportionate risk of HPV and associated cancers due to immune dysregulation, immunosuppression and…
  • Abstract Number: 1855 • ACR Convergence 2023

    Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia

    Gary Macfarlane1, Roxanne Cooksey2, Ernest Choy3 and Rosemary Hollick4, 1Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2Cardiff University, Cardiff, United Kingdom, 3Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, 4University of Aberdeen, Aberdeen, United Kingdom

    Background/Purpose: A large body of evidence has informed, internationally, management recommendations for people with fibromyalgia. However there are very few studies which have examined how…
  • Abstract Number: 0166 • ACR Convergence 2023

    Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States

    Zhiyi Li1, Elizabeth Marchlewicz2, Danae Black2, Hana Schwartz2, Yang Zhao1 and Erik Imel3, 1Kyowa Kirin North America, Bedminster, NJ, 2Merative, Cambridge, MA, 3Indiana University School of Medicine, Indianapolis, IN

    Background/Purpose: Familial hypophosphatemia (FH) is most commonly due to phosphate regulating endopeptidase X-linked (PHEX) gene mutations resulting in renal phosphate wasting, which leads to rickets,…
  • Abstract Number: 0806 • ACR Convergence 2023

    Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial

    Linda Li1, Hui Xie2, Lynne feehan1, Na Lu3, Alison Hoens4, Kelly English5, Eileen Davidson5, Catherine L. Backman6, Smruthi Ramachandran1, Ellen Wang1, Stephanie Therrien3, Julia Mucha1, Teresa Liu-Ambrose1, Kimberly Miller7, Christopher Shaw8 and Diane Lacaille9, 1University of British Columbia, Vancouver, BC, Canada, 2Simon Fraser University, Vancouver, BC, Canada, 3Arthritis Research Canada, Vancouver, BC, Canada, 4University of British Columbia, Richmond, BC, Canada, 5Arthritis Patient Advisory Board, Arthritis Research Canada, Vancouver, BC, Canada, 6The University of British Columbia, Vancouver, BC, Canada, 7BC Children’s and Women’s Hospital & Health Centre, Vancouver, BC, Canada, 8Simon Fraser University, Burnaby, BC, Canada, 9Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: To achieve optimal health outcomes, people with rheumatoid arthritis (RA) need to know their symptom patterns and be able to practice self-care activities. With…
  • Abstract Number: 1616 • ACR Convergence 2023

    Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies

    Joshua Skydel1, Reshma Ramachandran2, Sakinah Suttiratana2, Joseph Ross2, Joshua Wallach3 and Christopher Burns4, 1Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2Yale University, New Haven, CT, 3Emory University, Atlanta, GA, 4Dartmouth Hitchcock Medical Center, Lebanon, NH

    Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…
  • Abstract Number: 1858 • ACR Convergence 2023

    How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors?

    Nick Bansback1, Michael law1, Fiona Clemont2, Mina Tadrous3, Sandra Blitz1 and Mark Harrison1, 1University of British Columbia, Vancouver, BC, Canada, 2University of Calgary, Calgary, AB, Canada, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose: In response to the low uptake of biosimilars, British Columbia (BC) in Canada became the first jurisdiction in North America to require patients with…
  • Abstract Number: 0169 • ACR Convergence 2023

    Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective

    Alejandro Figueroa-Lara1, Mary Ann Aure2 and Carmen Andalucia1, 1Werfen, San Diego, CA, 2Werfen, Chula Vista, CA

    Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology